The Egyptian pharmaceutical industry remains
highly fragmented, introverted and in dire need of consolidation.
As an integral component of the government's health care strategy,
it will require to be profoundly restructured in the coming
years, with the looming TRIPS agreement, starting in 2005, imparting
an additional sense of urgency. The industry slowed considerably
in year 2000 both in volume and prices.
has investments in three of the most promising and profitable
companies of the industry:
Pharmaceutical Company is an established player with a solid
product line and a good audience in the private market.
is a fast growing newcomer with a strong position in the public
funded sector. The company has just completed a state of the
art manufacturing facility in Assiut, which is in the process
of gaining US FDA approval, a first for the country and region.
It is aggressively positioning itself for exports, an endeavor,
which has so far eluded all other industry participants.
has also a state in Otsuka, the Egyptian subsidiary of a large
Japanese Pharmaceutical Company, which is continuing to perform
recognition of the potential of the industry in the generic
drugs segment, CIIC is an active promoter and catalyst in the
eventual formation of a national company, capable of insuring
the basic local needs but equally able to capitalize on the
export potential in the developing world.